Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease

Study Overview
=================
Brief Summary
-----------------
We aim to clarify the relationship between sleep hygiene and the onset of sarcopenia or cognitive dysfunction using sleep time, arousal, and sleep quality as indicators in COPD or IPF patients, and clarify the effects of sleep hygiene on disease progression and life prognosis.

Detailed Description
-----------------
Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) have been reported to be associated with a high rate of sleep-related disorders such as insomnia, sleep-related hypoventilation, and sleep apnea syndrome.Sleep-related disorders cause symptoms such as daytime sleepiness, decreased ADL, and depression, which causes cognitive dysfunction. Both COPD and IPF have been reported to be associated with cognitive dysfunction. Recently, it has been focused on the relationship between sleep-related disorders and sarcopenia. The relationship between sleep hygiene, cognitive dysfunction, and sarcopenia in the patients with COPD or IPF is not well understood.

Official Title
-----------------
Examination of the Relationship Between Sleep Hygiene, Sarcopenia, and Cognitive Function in Patients With Chronic Obstructive Pulmonary Disease or Idiopathic Pulmonary Fibrosis

Conditions
-----------------
Sleep Hygiene, Sarcopenia, Cognitive Function, COPD, IPF

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with COPD or IPF. Exclusion Criteria: Subjects who have been hospitalized for exacerbation of respiratory failure within 1 month of study participation Subjects who have already been diagnosed with sarcopenia or cognitive dysfunction Subjects receiving long-term oxygen therapy (LTOT) or non-invasive ventilation therapy (NIV) Subjects with obstructive sleep apnea who are indicated for continuous positive airway pressure (CPAP) Subjects with severe complications such as cardiovascular disease, liver disease, renal disease, malignancy, and neurological disease.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between sleep time at study enrollment and onset of sarcopenia during follow-up period |  | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between sleep time at study enrollment and the onset of mild cognitive impairment during follow-up period |  | Two years | 
| Relationship between sleep efficiency, arousal at the time of study enrollment and the onset of sarcopenia and mild cognitive impairment during the follow-up period |  | Two years | 
| Association of sleep time, sleep efficiency, arousal at the time of study enrollment and hospitalization and death due to COPD exacerbations or IPF exacerbations during follow-up period |  | Two years | 
| Relationship between sleep time, sleep efficiency, arousal at the time of study enrollment and changes in grip strength, walking speed, skeletal muscle mass and cognitive function during follow-up period |  | Two years | 
| Relationship between sleep time, sleep efficiency, arousal at the time of study enrollment and changes in grip strength, walking speed, skeletal muscle mass and cognitive function at the time of study enrollment |  | Two years | 
| Factors associated with the onset of sarcopenia and mild cognitive impairment during follow-up period |  | Two years |